1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Neuromodulation Market by Technology & by Application - Trends & Global Forecast to 2020

Over the years, the global healthcare industry has witnessed a paradigm shift, and is now increasingly focused on minimally invasive therapies that not only treats a wide range of chronic and refractory disorders but also have fewer side effects. The demand for neuromodulation has increased significantly, because of patients’ preference for minimally invasive surgeries. Moreover, these therapies are reversible, which allows physicians to cease treatment, as and when required by removing the stimulating devices.

Based on technology, the internal neuromodulation segment is expected to be the largest and fastest-growing component segment in 2015. In internal neuromodulation category, spinal cord stimulation segment is expected to dominate the neuromodulation market in 2015. However, the deep brain stimulation segment is expected to grow at the highest CAGR from 2015 to 2020. In the external neuromodulation category, the transcutaneous electrical nerve stimulation segment is expected to be the largest segment in the neuromodulation market. However, the transcranial magnetic stimulation segment has registered the highest CAGR during the forecast period.


North America is expected to account for the largest share of the neuromodulation market, followed by Europe, Asia-Pacific, and rest of the world (RoW) in 2015. In the coming years, the neuromodulation market is expected to witness the highest growth rate in the Asian region, with emphasis on India, China, and Japan. These countries are expected to increase revenues for the manufacturers of equipment and devices involved in neuromodulation.

The global neuromodulation market witnesses high-competitive intensity as there are several big and small firms with similar product offerings. These companies adopt various strategies (agreements, partnerships, mergers, collaborations, acquisitions, new product launches, market development, geographical expansions, and acquisitions) to increase their market shares and establish a strong foothold in the global neuromodulation market.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps companies, garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

- Market Penetration: Comprehensive information on the product portfolios offered by top players in the neuromodulation market. The report analyzes the neuromodulation market by technology and application

- Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the neuromodulation market

- Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various neuromodulation technologies across regions

- Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the neuromodulation market

- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the neuromodulation market

Table Of Contents

Neuromodulation Market by Technology and by Application - Trends and Global Forecast to 2020
TABLE OF CONTENTS

1 INTRODUCTION 17
1.1 OBJECTIVES OF STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 18
1.3.2 YEARS CONSIDERED FOR THE STUDY 19
1.4 CURRENCY 19
1.5 LIMITATIONS 19
1.6 STAKEHOLDERS 19
2 RESEARCH METHODOLOGY 20
2.1 RESEARCH METHODOLOGY STEPS 20
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 21
2.2.1 SECONDARY RESEARCH 21
2.2.2 PRIMARY RESEARCH 22
2.2.2.1 Key data from primary sources 23
2.2.2.2 Key Insights from primary sources 23
2.2.2.3 Key industry insights 24
2.2.3 MARKET SIZE ESTIMATION METHODOLOGY 24
2.2.4 RESEARCH DESIGN 26
2.2.5 MARKET DATA VALIDATION AND TRIANGULATION 27
2.2.6 ASSUMPTIONS FOR THE STUDY 28
3 EXECUTIVE SUMMARY 29
3.1 INTRODUCTION 29
3.2 CURRENT SCENARIO 30
3.3 FUTURE OUTLOOK 31
3.4 CONCLUSION 34
4 PREMIUM INSIGHTS 35
4.1 GLOBAL NEUROMODULATION MARKET OVERVIEW 35
4.2 GLOBAL NEUROMODULATION MARKET, BY TYPE 35
4.3 GEOGRAPHIC ANALYSIS OF THE DEEP BRAIN STIMULATION MARKET, BY APPLICATION 36
4.4 INTERNAL NEUROMODULATION MARKET, BY MODALITY 37
4.5 GEOGRAPHICAL SNAPSHOT OF THE NEUROMODULATION MARKET 38

5 MARKET OVERVIEW 39
5.1 INTRODUCTION 40
5.2 MARKET SEGMENTATION 41
5.3 MARKET DYNAMICS 42
5.3.1 DRIVERS 42
5.3.1.1 Rising prevalence of neurological disorders to spur market growth 42
5.3.1.2 Unprecedented increase in the aging population to fuel market growth 43
5.3.1.3 Expanded target applications and new indications are expected to stimulate the growth of neuromodulation devices 43
5.3.1.4 Investments and funds - an impetus for market growth 43
5.3.2 RESTRAINTS 45
5.3.2.1 Unfavorable reimbursement scenario hinders market growth 45
5.3.2.2 Lack of trained professionals likely to hamper market growth 45
5.3.3 OPPORTUNITIES 46
5.3.3.1 Expansion in Emerging Economies 46
5.3.3.2 Strong product pipeline to propel the market 47
6 GLOBAL NEUROMODULATION MARKET, BY TECHNOLOGY 48
6.1 INTRODUCTION 49
6.2 INTERNAL NEUROMODULATION 50
6.2.1 SPINAL CORD STIMULATION (SCS) 53
6.2.2 DEEP BRAIN STIMULATION (DBS) 54
6.2.3 VAGUS NERVE STIMULATION (VNS) 55
6.2.4 SACRAL NERVE STIMULATION (SNS) 57
6.2.5 GASTRIC ELECTRICAL STIMULATION (GES) 58
6.3 EXTERNAL NEUROMODULATION (NON-INVASIVE) 60
6.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) 63
6.3.2 TRANSCRANIAL MAGNETIC STIMULATION (TMS) 64
6.3.3 RESPIRATORY ELECTRICAL STIMULATION (RES) 65
7 GLOBAL NEUROMODULATION MARKET, BY APPLICATION 67
7.1 INTRODUCTION 68
7.2 SPINAL CORD STIMULATION (SCS) MARKET, BY APPLICATION 69
7.2.1 FAILED BACK SYNDROME (FBSS) 69
7.2.2 CHRONIC PAIN 70
7.2.3 ISCHEMIA 70
7.3 DEEP BRAIN STIMULATION (DBS) MARKET, BY APPLICATION 71
7.3.1 PARKINSON'S DISEASE 71
7.3.2 TREMOR 72
7.3.3 DEPRESSION 72
7.3.4 OTHER DBS APPLICATIONS 72
7.4 SACRAL NERVE STIMULATION MARKET, BY APPLICATION 74
7.4.1 URINE INCONTINENCE 74
7.4.2 FECAL INCONTINENCE 74
7.5 VAGUS NERVE STIMULATION MARKET, BY APPLICATION 75
7.5.1 EPILEPSY 75
7.5.2 OTHER VNS APPLICATIONS 75
7.6 GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION 76
7.6.1 GASTROPARESIS 76
7.6.2 OBESITY 77
7.7 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY APPLICATION 78
7.7.1 TREATMENT RESISTANT DEPRESSION 78
7.7.2 OTHER TENS APPLICATIONS 78
7.8 REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY APPLICATION 79
7.8.1 DEPRESSION 79
7.8.2 MIGRAINE HEADACHE 79
7.9 RESPIRATORY ELECTRICAL STIMULATION MARKET, BY APPLICATION 80
7.9.1 SPINAL CORD INJURY 80
8 NEUROMODULATION MARKET, BY REGION 81
8.1 INTRODUCTION 82
8.2 NORTH AMERICA 84
8.2.1 U.S. 87
8.2.1.1 Rising prevalence of chronic diseases in the U.S. 87
8.2.1.2 Increasing aging population in the U.S. 87
8.2.1.3 Increasing Lyme disease cases in the U.S. 88
8.2.1.4 Conferences and annual meetings to increase exposure of neuromodulation 88
8.2.2 CANADA 90
8.2.2.1 Increasing incidence of Lyme disease in Canada 90
8.2.2.2 Increasing incidences of cancer and diabetes 90
8.3 EUROPE 92
8.3.1 RAPIDLY AGING POPULATION IN EUROPE 92
8.3.1.1 Conferences and annual meetings to increase exposure to Neuromodulation in the European market 92
8.3.2 GERMANY 96
8.3.2.1 Rising prevalence of Parkinson's disease in Germany 96
8.3.3 U.K. 98
8.3.3.1 Rising Prevalence of Diabetes in the U.K. 98
8.3.3.2 Rise in CVD prevalence in the U.K. 98
8.3.4 FRANCE 100
8.3.4.1 Rising incidences of Alzheimer's disease and dementia 100

8.3.5 REST OF EUROPE 101
8.3.5.1 High diabetes prevalence in Russia, Turkey, Poland, Romania, and Ukraine 101
8.4 ASIA-PACIFIC 103
8.4.1 JAPAN 106
8.4.1.1 Rising adoption of neurostimulation 106
8.4.2 CHINA 108
8.4.2.1 High diabetes incidences and rapidly aging population 108
8.4.3 INDIA 109
8.4.3.1 Increasing geriatric population and high diabetes incidence 109
8.4.3.2 Conferences on neuromodulation and pain management in India 109
8.4.4 REST OF ASIA-PACIFIC (ROAPAC) 111
8.4.4.1 Increasing prevalence Of Parkinson's disease in Singapore 111
8.4.4.2 Conferences on neuromodulation in Australia 111
8.5 REST OF THE WORLD 113
8.5.1 INCREASING INCIDENCES OF CANCER IN LATIN AMERICA 114
8.5.2 RISE IN AGING POPULATION and PREVALENCE OF DIABETES 114
9 COMPETITIVE LANDSCAPE 116
9.1 OVERVIEW 116
9.2 MARKET SHARE ANALYSIS, BY KEY PLAYER 116
9.2.1 INTRODUCTION 116
9.3 MEDTRONIC, INC. 117
9.4 BOSTON SCIENTIFIC CORPORATION 118
9.5 ST. JUDE MEDICAL, INC. 119
9.6 COMPETITIVE SCENARIO 120
9.6.1 MARKET DEVELOPMENT 121
9.6.2 AGREEMENTS, COLLABORATIONS, MERGERS, AND PARTNERSHIPS 122
9.6.3 NEW PRODUCT LAUNCHES 123
9.6.4 ACQUISITIONS 124
9.6.5 EXPANSION 125
10 COMPANY PROFILES 126
(Overview, Financials, Products and Services, Strategy, and Developments)*
10.1 INTRODUCTION 126
10.2 MEDTRONIC, INC. 127
10.3 BOSTON SCIENTIFIC CORPORATION 130
10.4 ST. JUDE MEDICAL, INC. 133
10.5 CYBERONICS, INC. 136
10.6 NEVRO CORPORATION 138
10.7 NEUROSIGMA, INC. 140
10.8 NEUROPACE, INC. 142
10.9 BIOCONTROL MEDICAL 144
10.10 SYNAPSE BIOMEDICAL, INC. 146
10.11 NEURONETICS, INC. 148

*Details on Financials, Product and Services, Strategy, and Developments might not be captured in case of unlisted companies.
11 APPENDIX 150
11.1 DISCUSSION GUIDE 150
11.2 COMPANY DEVELOPMENTS (2012-2015) 155
11.2.1 MEDTRONIC, INC. 155
11.2.2 BOSTON SCIENTIFIC CORPORATION 155
11.2.3 ST JUDE MEDICAL, INC. 156
11.2.4 NEUROSIGMA, INC. 156
11.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 157
11.4 AVAILABLE CUSTOMIZATIONS 157
11.5 RELATED REPORTS 158


LIST OF TABLES

TABLE 1 INCREASING INCIDENCE OF NEUROLOGICAL DISORDERS IS PROPELLING THE GROWTH OF THE GLOBAL NEUROMODULATION MARKET 44
TABLE 2 UNFAVOURABLE REIMBURSEMENT STRUCTURE IS RESTRAINING THE GROWTH OF THE GLOBAL NEUROMODULATION MARKET 46
TABLE 3 EXPANSION IN EMERGING MARKETS HAS A HUGE POTENTIAL FOR GROWTH IN THE GLOBAL NEUROMODULATION MARKET 47
TABLE 4 GLOBAL NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 49
TABLE 5 INTERNAL NEUROMODULATION MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 50
TABLE 6 INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 ($MILLION) 51
TABLE 7 INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 (UNITS) 52
TABLE 8 SPINAL CORD STIMULATION MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 53
TABLE 9 SPINAL CORD STIMULATION MARKET SIZE, 2013-2020 (UNITS) 54
TABLE 10 DEEP BRAIN STIMULATION MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 55
TABLE 11 DEEP BRAIN STIMULATION MARKET SIZE, BY REGION, 2013-2020 (UNITS) 55
TABLE 12 VAGUS NERVE STIMULATION MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 56
TABLE 13 VAGUS NERVE STIMULATION MARKET SIZE, BY REGION, 2013-2020 (UNITS) 56
TABLE 14 SACRAL NERVE STIMULATION MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 57
TABLE 15 SACRAL NERVE STIMULATION MARKET SIZE, BY REGION, 2013-2020 (UNITS) 58
TABLE 16 GASTRIC ELECTRICAL STIMULATION MARKET SIZE, BY REGION,
2013-2020 ($MILLION) 59
TABLE 17 GASTRIC ELECTRICAL STIMULATION MARKET SIZE, BY REGION,
2013-2020 (UNITS) 59
TABLE 18 EXTERNAL NEUROMODULATION MARKET SIZE, BY REGION,
2013-2020 ($MILLION) 60
TABLE 19 EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 61
TABLE 20 EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY, 2013-2020 (UNITS) 62
TABLE 21 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET SIZE,
BY REGION, 2013-2020 ($MILLION) 63
TABLE 22 GASTRIC ELECTRICAL STIMULATION MARKET SIZE, BY REGION,
2013-2020 (UNITS) 64
TABLE 23 TRANSCRANIAL MAGNETIC STIMULATION MARKET SIZE, BY REGION,
2013-2020 ($MILLION) 65
TABLE 24 TRANSCRANIAL MAGNETIC STIMULATION MARKET SIZE, BY REGION,
2013-2020 (UNITS) 65
TABLE 25 RESPIRATORY ELECTRICAL STIMULATION MARKET SIZE, BY REGION,
2013-2020 ($MILLION) 66
TABLE 26 RESPIRATORY ELECTRICAL STIMULATION MARKET SIZE, BY REGION,
2013-2020 (UNITS) 66
TABLE 27 GLOBAL SPINAL CORD STIMULATION MARKET, BY APPLICATION,
2013-2020 ($MILLION) 71
TABLE 28 GLOBAL DEEP BRAIN STIMULATION MARKET, BY APPLICATION,
2013-2020 ($MILLION) 73
TABLE 29 GLOBAL SACRAL NERVE STIMULATION MARKET, BY APPLICATION,
2013-2020 ($MILLION) 75
TABLE 30 GLOBAL VAGUS NERVE STIMULATION MARKET, BY APPLICATION,
2013-2020 ($MILLION) 76
TABLE 31 GLOBAL GASTRIC ELECTRICAL STIMULATION MARKET, BY APPLICATION,
2013-2020 ($MILLION) 77
TABLE 32 GLOBAL TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET,
BY APPLICATION, 2013-2020 ($MILLION) 78
TABLE 33 GLOBAL TRANSCRANIAL MAGNETIC STIMULATION MARKET,
BY APPLICATION, 2013-2020 ($MILLION) 79
TABLE 34 NEUROMODULATION MARKET SIZE, BY REGION, 2013-2020($MILLION) 82
TABLE 35 NORTH AMERICA: NEUROMODULATION MARKET SIZE, BY COUNTRY,
2013-2020 ($MILLION) 84
TABLE 36 NORTH AMERICA: NEUROMODULATION MARKET SIZE, BY TYPE,
2013-2020 ($MILLION) 86
TABLE 37 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET SIZE,
BY MODALITY, 2013-2020 ($MILLION) 86
TABLE 38 NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET SIZE,
BY MODALITY, 2013-2020 ($MILLION) 87
TABLE 39 U.S.: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 88
TABLE 40 U.S.: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 89
TABLE 41 U.S. : EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 89
TABLE 42 CANADA: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 90
TABLE 43 CANADA : INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 91
TABLE 44 CANADA: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 91
TABLE 45 EUROPE: NEUROMODULATION MARKET SIZE, BY COUNTRY,
2013-2020 ($MILLION) 93
TABLE 46 EUROPE: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 95
TABLE 47 EUROPE: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 95
TABLE 48 EUROPE: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 96
TABLE 49 GERMANY: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 96
TABLE 50 GERMANY: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 97
TABLE 51 GERMANY: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 97
TABLE 52 U.K.: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 98
TABLE 53 U.K.: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 99
TABLE 54 U.K.: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 99
TABLE 55 FRANCE: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 100
TABLE 56 FRANCE: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 100
TABLE 57 FRANCE: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 101
TABLE 58 REST OF EUROPE: NEUROMODULATION MARKET SIZE, BY TYPE,
2013-2020 ($MILLION) 101
TABLE 59 REST OF EUROPE: INTERNAL NEUROMODULATION MARKET SIZE,
BY MODALITY, 2013-2020 ($MILLION) 102
TABLE 60 REST OF EUROPE: EXTERNAL NEUROMODULATION MARKET SIZE,
BY MODALITY, 2013-2020 ($MILLION) 102
TABLE 61 ASIA-PACIFIC: NEUROMODULATION MARKET SIZE, BY COUNTRY,
2013-2020 ($MILLION) 103
TABLE 62 ASIA-PACIFIC: NEUROMODULATION MARKET SIZE, BY TYPE,
2013-2020 ($MILLION) 105
TABLE 63 ASIA-PACIFIC: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 105
TABLE 64 ASIA-PACIFIC: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 106
TABLE 65 JAPAN: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 106
TABLE 66 JAPAN: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 107
TABLE 67 JAPAN: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 107
TABLE 68 CHINA: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 108
TABLE 69 CHINA: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 108
TABLE 70 CHINA: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 109
TABLE 71 INDIA: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 110
TABLE 72 INDIA: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 110
TABLE 73 INDIA: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 111
TABLE 74 ROAPAC: NEUROMODULATION MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 111
TABLE 75 ROAPAC: INTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 112
TABLE 76 ROAPAC: EXTERNAL NEUROMODULATION MARKET SIZE, BY MODALITY,
2013-2020 ($MILLION) 112
TABLE 77 REST OF THE WORLD: NEUROMODULATION MARKET SIZE, BY TYPE,
2013-2020 ($MILLION) 114
TABLE 78 REST OF THE WORLD: INTERNAL NEUROMODULATION MARKET SIZE,
BY MODALITY, 2013-2020 ($MILLION) 115
TABLE 79 REST OF THE WORLD: EXTERNAL NEUROMODULATION MARKET SIZE,
BY MODALITY, 2013-2020 ($MILLION) 115
TABLE 80 RECENT DEVELOPMENTS, 2012-2014 121
TABLE 81 RECENT DEVELOPMENTS, 2012-2014 122
TABLE 82 RECENT DEVELOPMENTS, 2012-2014 123
TABLE 83 RECENT DEVELOPMENTS, 2012-2014 124
TABLE 84 RECENT DEVELOPMENTS, 2012-2014 125


LIST OF FIGURES

FIGURE 1 NEUROMODULATION MARKET SEGMENTATION 18
FIGURE 2 GLOBAL NEUROMODULATION MARKET: RESEARCH METHODOLOGY STEPS 20
FIGURE 3 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 22
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 25
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 25
FIGURE 6 DATA TRIANGULATION METHODOLOGY 27
FIGURE 7 INTERNAL NEUROMODULATION SEGMENT TO WITNESS THE HIGHEST CAGR DURING THE FORECAST PERIOD 29
FIGURE 8 DEEP BRAIN STIMULATION TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 31
FIGURE 9 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION IS EXPECTED TO COMMAND THE LARGEST SHARE IN 2015 32
FIGURE 10 PARKINSON'S DISEASE IS EXPECTED TO COMMAND THE LARGEST SHARE IN 2015 33
FIGURE 11 ASIA-PACIFIC SLATED TO WITNESS THE HIGHEST GROWTH IN THE NEUROMODULATION MARKET DURING THE FORECAST PERIOD 34
FIGURE 12 ATTRACTIVE OPPORTUNITIES IN THE NEUROMODULATION MARKET 35
FIGURE 13 INTERNAL MODULATION TECHNOLOGY TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 35
FIGURE 14 NORTH AMERICA TO DOMINATE THE NEUROMODULATION MARKET 36
FIGURE 15 DEEP BRAIN STIMULATION SEGMENT TO WITNESS HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 37
FIGURE 16 ASIA-PACIFIC TO WITNESS HIGHEST GROWTH RATE FROM 2015 TO 2020 38
FIGURE 17 DRIVERS, RESTRAINTS and OPPORTUNITIES 42
FIGURE 18 GLOBAL NEUROMODULATION MARKET, BY TYPE 49
FIGURE 19 INTERNAL NEUROMODULATION SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 50
FIGURE 20 ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 51
FIGURE 21 DEEP BRAIN STIMULATION TO GROWTH AT A HIGHEST CAGR DURING THE FORECAST PERIOD 52
FIGURE 22 ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 61
FIGURE 23 TRANSCRANIAL MAGNETIC STIMULATION TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 62
FIGURE 24 GLOBAL INTERNAL NEUROMODULATION MARKET, BY APPLICATION 68
FIGURE 25 GLOBAL EXTERNAL NEUROMODULATION MARKET, BY APPLICATION 69
FIGURE 26 NORTH AMERICA IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE GLOBAL NEUROMODULATION MARKET IN 2015 83
FIGURE 27 U.S. TO WITNESS THE HIGHEST GROWTH IN THE GLOBAL NEUROMODULATION MARKET IN NORTH AMERICA (2015) 85
FIGURE 28 GERMANY TO WITNESS THE HIGHEST GROWTH IN THE GLOBAL NEUROMODULATION MARKET IN EUROPE (2015) 94
FIGURE 29 ASIA-PACIFIC, THE FASTEST-GROWING SEGMENT IN THE GLOBAL MARKET 104
FIGURE 30 ROW EXPECTED TO GROW AT A CAGR DURING 2015 TO 2020 113
FIGURE 31 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014 116
FIGURE 32 STRATEGIES ADOPTED BY KEY PLAYERS OVER THE LAST FOUR YEARS (2012-2015) 120
FIGURE 33 BATTLE FOR MARKET SHARE: MARKET DEVELPOMENT WAS THE KEY STRATEGY 121
FIGURE 34 GEOGRAPHICAL REVENUE MIX OF TOP PLAYERS 126
FIGURE 35 MEDTRONIC, INC.: COMPANY SNAPSHOT 127
FIGURE 36 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 130
FIGURE 37 ST JUDE MEDICAL, INC.: COMPANY SNAPSHOT 133
FIGURE 38 CYBERONICS, INC.: COMPANY SNAPSHOT 136
FIGURE 39 NEVRO CORPORATION: COMPANY SNAPSHOT 138

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Epilepsy  - Market Insights, Epidemiology and Market Forecast-2023

Epilepsy  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Epilepsy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...

Narcolepsy-Market Insights, Epidemiology and Market Forecast-2023

Narcolepsy-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Narcolepsy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.